Drug Profile
YHR 1706
Alternative Names: YHR1706Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Yuhan
- Class Antihyperglycaemics; Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dyslipidaemias; Type 2 diabetes mellitus
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for phase-I development in Dyslipidaemias(Combination therapy, In volunteers) in South Korea (PO)
- 28 Sep 2020 No recent reports of development identified for phase-I development in Dyslipidaemias(Monotherapy, In volunteers) in South Korea (PO)
- 28 Sep 2020 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(Combination therapy, In volunteers) in South Korea (PO)